DiagnoCure receives positive results from ImmunoCyt
DiagnoCure Inc CUR
Shares issued 17,498,032 Apr 18 close $2.00
Thu 19 Apr 2001 News Release
Mr. Pierre Desy reports
DiagnoCure has had positive clinical performance of ImmunoCyt when used in
conjunction with cytology in the detection of upper urinary tract
transitional cell carcinoma (UT-TCC).
Dr. Michele Lodde, a member of the team led by the Prof. Michael Marberger,
PhD, at the department of urology and clinical pathology at the University
of Vienna, Austria, presented the results of this independent study at the
European Association of Urology Convention in Geneva last week. Dr.
Marberger is well respected within the international community of
urologists and pathologists.
This independent study involved 37 patients with symptoms and/or findings
on imaging that are suggestive of upper tract cancer. The study assesses
the value of ImmunoCyt in conjunction with cytology in detecting these
tumours, mainly because of ImmunoCyt's high sensitivity to low-grade
cancer. The combination of ImmunoCyt and cytology gives 88-per-cent
sensitivity on voided specimens while providing 100-per-cent sensitivity
and specificity on urine collected directly from the ureters.
The study concluded that patients with upper tract cancer are at a high
risk of later developing tumours of the bladder. Likewise, previous tumours
of the bladder may be followed by upper tract manifestations of cancer. Up
to 29 per cent of patients with high-risk superficial bladder tumours have
been reported to develop upper tract cancer in 15 years. These results
provide evidence in support of claims that the upper tract should be
monitored following the initial diagnosis.
"The high precision achieved with ImmunoCyt potentially reduces the need
for more invasive instrumentation of the upper urinary tract in order to
rule out the presence of tumours," said Dr. Marberger. During the same
meeting, Dr. Marberger also presented the results from his department's use
of ImmunoCyt in the followup of patients previously diagnosed with bladder
cancer. "We are very satisfied with the sensitivity of ImmunoCyt to detect
bladder tumour recurrences, which assists us in better managing our
patients," Dr. Marberger added.
(c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com |
